QSAM Biosciences Provides 2022 Update and 2023 Milestones to Shareholders

January 10, 2023

AUSTIN, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) — QSAM Biosciences Inc. (OTCQB:QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases, today provides the following update to shareholders regarding progress made in 2022 and milestone goals for 2023.

Read more at globenewswire.com

Related news for (QSAM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.